HBR

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

Retrieved on: 
Monday, June 27, 2022
Review, FDA, Assistant, CRL, Patient, Adult, Research, Infection, Cutis verticis gyrata, Biomedical Advanced Research and Development Authority, Therapy, Endpoint security, Trial of the century, GLOBE, COVID-19, Pyelonephritis, Degenerative disease, Program, U.S. Securities and Exchange Commission, Tebipenem, Risk, Food, Partnership, HBR, Nasdaq, Urinary tract infection, Human services, Preparedness, New Drug Application, PDUFA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Medical device, Vaccine, Spero

The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.

Key Points: 
  • The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.
  • In the CRL, the FDA ultimately concluded that Speros Phase 3 cUTI study of tebipenem HBr (ADAPT-PO) was insufficient to support approval and that additional clinical study would be required.
  • Spero intends to promptly request a Type A meeting with the FDA, to gain further insights as to the pathway forward towards a potential regulatory approval for tebipenem HBr.
  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

What the Transcendentalists Can Teach Us About Leadership: A Vanguard Network Dialogue on June 30, 2022

Retrieved on: 
Monday, June 27, 2022
Leadership, Schering-Plough, CEO, Chief executive officer, History of the United States, Corporate title, GC, NEW, The Vanguard Group, HBR, Nightclub, Management, Walgreens, Tenneco, United Airlines, Vanguard

This session -- the latest in Vanguard's "A Different Kind of Leadership" series, will be led by professor and eminent historian Robert A. Gross. Bob's recent work examines New England writers — notably, Ralph Waldo Emerson, Henry David Thoreau, and Emily Dickinson — in historical context. From that project has come his latest book "The Transcendentalists and Their World."

Key Points: 
  • Gross on June 30 from 4 - 5:30 PM ET, for an online dialogue, as part of the "A Different Kind of Leadership" series.
  • NEW YORK, June 27, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network today announced an online dialogue focused on the leadership lessons from the transcendentalists: Ralph Waldo Emerson, Henry David Thoreau, Nathaniel Hawthorne, and the Alcotts, among others.
  • This session -- the latest in Vanguard's "A Different Kind of Leadership" series, will be led by professor and eminent historian Robert A.
  • "It may seem unlikely to look to 19th century philosophers for contemporary leadership lessons," said Ken Banta, founder and principal of The Vanguard Network.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Monday, June 27, 2022
Review, FDA, Defendant, Court, Therapy, Workforce, GLOBE, Company, Suite, Tebipenem, Lists of schools in England, Food, HBR, GPM, Urinary tract infection, New Drug Application, NASDAQ, Time, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Medical device, Pharmaceutical industry, Spero

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

TBWA Unveils Future of Creative Work Research at Cannes Lions Festival of Creativity

Retrieved on: 
Monday, June 20, 2022
GMR, Time, Industry, HBR, Work–life balance in Germany, Fast Company, Culture, Spirituality, Global, Workplace, World, Macdonald, Creativity, Fresh Talent – Working in Scotland Scheme, Singapore Airlines, TBWA, Adidas, Omnicom Group, Henkel, OMC, EX, Goal, Research, LinkedIn, Work, Growth, Mental health, Apple, Forrester, Twitter, McDonald's, Adweek, Instagram, TRO, NYSE, Glassdoor, DAN, Life, Creative industries, Toy, Tourism, Design, Health insurance, Public relations, Marketing, Gatorade, Nissan

CANNES, France, June 20, 2022 /PRNewswire/ -- TBWA\Worldwide has today released a global study on the Future of Creative Work, revealing how creative talent feels about the state of the workplace, and what companies can do to make it better for employees.

Key Points: 
  • "But for agencies and creative companies to be leading this progress, our work cultures need to evolve, quickly."
  • Our talent is asking us to respect their time and mental space, to provide financial stability, and to deliver a better daily experience of creative work."
  • To put this research into context, the study looked at relevant EdgesTBWA's term for a meaningful cultural shift.
  • Anyone interested in advancing the Future of Creative Work agenda can contribute comments and ideas directly in the report .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP Auto, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 20, 2022
Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dentsply Sirona, Degenerative disease, Defendant, Marketing, Workforce, Documentation, GLOBE, Complaint, Review, NDA, Tebipenem, Mission statement, Audit committee, ASP, Medicare, Class Action, Annual report, Physician, Complicated, NASDAQ, XRAY, Treatment, News, SEC, Board, Justice, Income, LMP, HBR, FDA, COVID-19, Kidney, Government, Superior, Spero, Infection, Plaque, Anesthetic, Patient, Risk, CDNA, Relevant, Lists of schools in England, Company, Growth, New Drug Application, Urinary tract infection, Food, Sale, California superior courts, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • For more information on the LMP class action go to: https://bespc.com/cases/LMPX
    Dentsply is a dental equipment manufacturer with offices across the United States.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

OUTBio! Why it Matters: A Vanguard Dialogue with Paul Hastings on June 21

Retrieved on: 
Saturday, June 18, 2022
Vanguard, Industry, Education, HBR, NEW, LGBTQ, CEO, Schering-Plough, BIO, Leadership, Chief executive officer, The Vanguard Group, GC, Gay pride, Therapy, Organization, Mobile phone, Management, United Airlines, Tenneco, Walgreens

NEW YORK, June 18, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network will present an online interactive dialogue on the contributions of LGBTQ professionals in biotech and life sciences. The June 21 event, from 5 to 6 pm ET, will feature Paul Hastings, a leading advocate for diversity and driver of OUTBio!, the largest LGBTQ professionals group in the industry.

Key Points: 
  • Join this interactive online Vanguard dialogue with Paul Hastings, chair of BIO; CEO of Nkarta and key sponsor of OUTBio!, the biotech industry's largest LGBTQ professionals group.
  • NEW YORK, June 18, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network will present an online interactive dialogue on the contributions of LGBTQ professionals in biotech and life sciences.
  • The June 21 event, from 5 to 6 pm ET, will feature Paul Hastings , a leading advocate for diversity and driver of OUTBio!, the largest LGBTQ professionals group in the industry.
  • "No one can speak with more authority about the value derived from LGBTQ professionals than Paul Hastings."

Spero Therapeutics, Inc. Investor News: Robbins LLP is Investigating Spero Therapeutics, Inc. (SPRO) on Behalf of Shareholders

Retrieved on: 
Thursday, June 16, 2022
Legal, Professional Services, Steps, Population, HBR, Review, FDA, NDA, Tebipenem, MDR, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Infection, Failure, LCM, NASDAQ, News, Urinary tract infection, Workforce, Food, Patient, Therapy, Pharmaceutical industry, Spero

Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Key Points: 
  • Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections.
  • If you would like more information about Spero Therapeutics, Inc.'s misconduct, click here .
  • Next Steps: If you acquired shares of Spero Therapeutics, Inc. (SPRO) securities between October 28, 2021 and May 2, 2022, you have legal options.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP Automotive, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 14, 2022
New Drug Application, Mission statement, Company, Workforce, Sale, Review, COVID-19, Tebipenem, Superior, California superior courts, HBR, Marketing, Infection, Food, Income, Degenerative disease, Urinary tract infection, Spero, Population, LMP, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Relevant, Kidney, Audit committee, Class Action, Government, Physician, Justice, Patient, XRAY, Plaque, SEC, Complaint, CDNA, Anesthetic, Annual report, Medicare, Complicated, News, Treatment, Dentsply Sirona, FDA, Growth, ASP, GLOBE, Defendant, Risk, NASDAQ, Board, Lists of schools in England, Documentation, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, Pyelonephritis, P.C

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • For more information on the LMP class action go to: https://bespc.com/cases/LMPX
    Dentsply is a dental equipment manufacturer with offices across the United States.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Monday, June 13, 2022
New Drug Application, Ext, District court, Company, HBR, Securities Exchange Act of 1934, Complaint, Infection, Food, Court, Complicated, News, Treatment, Lists of action films, Workforce, FDA, GLOBE, Patient, SEC Rule 10b-5, Urinary tract infection, Review, Tebipenem, NASDAQ, Population, Lists of schools in England, NDA, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLP, Person, Pomerantz, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SPRO Investor Update: Robbins LLP Reminds Shareholders Lead Plaintiff Deadline in Class Action Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Saturday, June 11, 2022
Steps, Company, HBR, Securities Exchange Act of 1934, Infection, Food, News, MDR, Failure, Workforce, Therapy, FDA, GLOBE, Patient, Urinary tract infection, Review, Spero, NASDAQ, SAN, LCM, Population, NDA, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Pharmaceutical industry, Generic drug, Tebipenem

Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Key Points: 
  • Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections.
  • If you would like more information about Spero Therapeutics, Inc.'s misconduct, click here .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.